StockData
Kairos Pharma, LTD. logo

Kairos Pharma, LTD. (KAPA) stock

KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.44+0.04 (+10.08%)

Close on Nov 18, 2026Market cap $1.64MP/E –Yield –

Kairos Pharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Kairos Pharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$4.11M. For fiscal 2025 it was -$3.44M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$3.44M–
FY2024Dec 31, 2024-$3.96M-4982.7%
FY2023Dec 31, 2023$81.00K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$979.00K–
Q2 FY2026Jun 30, 2026-$1.01M–
Q1 FY2026Mar 31, 2026-$1.04M–
Q4 FY2025Dec 31, 2025-$1.08M–
Q3 FY2025Sep 30, 2025-$838.00K–
Q2 FY2025Jun 30, 2025-$805.00K–
Q1 FY2025Mar 31, 2025-$714.00K-2083.3%
Q4 FY2024Dec 31, 2024-$1.80M-2831.8%
Q3 FY2024Sep 30, 2024-$2.02M–
Q2 FY2024Jun 30, 2024-$168.00K–
Q1 FY2024Mar 31, 2024$36.00K–
Q4 FY2023Dec 31, 2023$66.00K–

More Kairos Pharma figures

See a number that looks wrong?